Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment

Lange, Matthias

prikaz prve stranice dokumenta Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment

Preuzmi
PDF 1.59 MB

diplomski rad

Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment

Split: Sveučilište u Splitu, Medicinski fakultet, 2021. urn:nbn:hr:171:067672

Lange, Matthias

Sveučilište u Splitu
Medicinski fakultet
Medicinska kemija i biokemija

Citirajte ovaj rad

APA 6th Edition

Lange, M. (2021). Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment (Diplomski rad). Split: Sveučilište u Splitu, Medicinski fakultet. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:171:067672

MLA 8th Edition

Lange, Matthias. "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment." Diplomski rad, Sveučilište u Splitu, Medicinski fakultet, 2021. https://urn.nsk.hr/urn:nbn:hr:171:067672

Chicago 17th Edition

Harvard

Lange, M. (2021). 'Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment', Diplomski rad, Sveučilište u Splitu, Medicinski fakultet, citirano: 06.11.2024., https://urn.nsk.hr/urn:nbn:hr:171:067672

Vancouver

Lange M. Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment [Diplomski rad]. Split: Sveučilište u Splitu, Medicinski fakultet; 2021 [pristupljeno 06.11.2024.] Dostupno na: https://urn.nsk.hr/urn:nbn:hr:171:067672

IEEE

M. Lange, "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment", Diplomski rad, Sveučilište u Splitu, Medicinski fakultet, Split, 2021. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:171:067672

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:171:067672

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.

Podaci o radu

Naslov	Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment
Naslov (hrvatski)	Izrazita ekspresija GD3 u subpopulacijama raka dojke nakon liječenja novim derivatom tieno[2,3-b]piridina
Autor	Matthias Lange
Mentor	Vedrana Čikeš Čulić (mentor)
Član povjerenstva	Anita Markotić (predsjednik povjerenstva)
Član povjerenstva	Nikolina Režić Mužinić (član povjerenstva)
Član povjerenstva	Renata Pecotić (član povjerenstva)
Ustanova koja je dodijelila akademski / stručni stupanj	Sveučilište u Splitu Medicinski fakultet (Medicinska kemija i biokemija) Split
Datum i država obrane	2021-07-16, Hrvatska
Znanstveno / umjetničko područje, polje i grana	BIOMEDICINA I ZDRAVSTVO Temeljne medicinske znanosti Medicinska biokemija
Sažetak	Objectives: The goal of this study was to determine GD3 expression after treatment with the novel thieno[2,3-b]pyridine derivative, by focusing on CD44+/CD24- CSCs, CD44- epithelial cells, as well as CD44+/ CD24+ hybrid cells. Methods: The MDA-MB-231 cell line was treated with 3-amino-N-(3-chloro-2- methylphenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-b]quinoline-2-carboxamide (compound 1). Cells were plated onto six-well plates and treated with 2 M compound 1 for 48 h. Following this, cells were stained with anti-GD3, anti-CD44 and anti-CD24 antibodies, and then analyzed via flow cytometry. The acquisition of data of triple-stained samples was done by a BD Accuri C6 cytometer (BD Biosciences) and analyzed with the FlowLogic Software. Results: Treatment of MDA-MB-231 cells with compound 1 has led to a reduction of the expression of GD3 in CD44+/CD24- CSCs, as well as CD44- epithelial cells. GD3 expression in CD44+/CD24+ hybrid cells was not significantly reduced. Conclusion: Due to its ability to reduce GD3 expression in different breast cancer subpopulations, compound 1 has a potential to be used in the treatment of triple-negative breast cancer.
Sažetak (hrvatski)	Ciljevi: Cilj ove studije bio je utvrditi ekspresiju GD3 nakon tretmana novim derivatom tieno[2,3-b]piridina, posebice na CD44+/CD24- matičnim stanicama raka (CSC), CD44- epitelnim stanicama, kao i CD44+/CD24+ hibridnim stanicama. Metode: Stanična linija MDA-MB-231 tretirana je s 3-amino-N-(3-kloro-2-metilfenil)-5- okso-5,6,7,8-tetrahidrotienom[2,3-b]kinolin-2-karboksamid (spoj 1). Stanice su nasađene na ploče sa šest jažica i tretirane s 2 M spojem 1 tijekom 48 sati. Nakon toga, stanice su obojane s protu-GD3, protu-CD44 i protu-CD24 protutijelima, a zatim analizirane protočnom citometrijom. Prikupljanje podataka trostruko obojenih stanica rađeno je citometrom BD Accuri C6 (BD Biosciences) i analizirano softverom FlowLogic. Rezultati: Tretman MDA-MB-231 stanica spojem 1 doveo je do smanjenja ekspresije GD3 na CD44+/CD24- CSC, kao i CD44- epitelnim stanicama. Ekspresija GD3 na hibridnim stanicama CD44+/CD24+ nije bila značajno smanjena. Zaključak: Zbog svoje sposobnosti smanjenja ekspresije GD3 u različitim subpopulacijama raka dojke, spoj 1 ima potencijal za upotrebu u liječenju trostruko-negativnog raka dojke.
Ključne riječi
Ključne riječi (hrvatski)
Jezik	engleski
URN:NBN	urn:nbn:hr:171:067672
Studijski program	Naziv: Medicina na engleskom jeziku Vrsta studija: sveučilišni Stupanj studija: integrirani preddiplomski i diplomski Akademski / stručni naziv: doktor/doktorica medicine (dr. med.)
Vrsta resursa	Tekst
Način izrade datoteke	Izvorno digitalna
Prava pristupa	Otvoreni pristup
Uvjeti korištenja
Repozitorij	Repozitorij MEFST
Datum i vrijeme pohrane	2021-07-19 13:18:46